Garenoxacin
Garenoxacin Basic information
- Product Name:
- Garenoxacin
- Synonyms:
-
- 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid methanesulfonate hydrate
- Garenoxacin mesylate hydrate
- Garenoxacin mesylate hydrate 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid methanesulfonate hydrate
- (R)-1-cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound with methanesulfonic acid (1:1) hydrate
- 1-cyclopropyl-8-(difluoromethoxy)-4-keto-7-[(1R)-1-methylisoindolin-5-yl]quinoline-3-carboxylic acid
- BMS284756 (Mesylate hydrate)
- Garenoxacin mesylate [USAN]
- Garenoxacin mesylate monohydrate >=98% (HPLC)
- CAS:
- 223652-90-2
- MF:
- C23H20F2N2O4.CH4O3S.H2O
- MW:
- 540.53
- Mol File:
- 223652-90-2.mol
Garenoxacin Chemical Properties
- storage temp.
- 2-8°C
- solubility
- DMSO:100.0(Max Conc. mg/mL);185.0(Max Conc. mM)
Water:12.5(Max Conc. mg/mL);23.13(Max Conc. mM) - form
- powder
- color
- white to beige
- Water Solubility
- H2O: 10mg/mL, clear (warmed)
Garenoxacin Usage And Synthesis
Uses
Antibacterial agent.
Biological Activity
Garenoxacin is a broad spectrum fluoroquinolone antibiotic suitable for treatment of gram-positive and gram-negative bacterial infections. Garenoxacin has a low mutant prevention concentration and a narrow mutant selection window. Data shows th at garenoxacin has anti-inflammatory properties. It significantly alleviates LPS-induced IL-8 production through the negative regulation of the ERK1/2 pathway both in the human airway epithelial cell line A549 and the monocyte cell line THP-1.
in vivo
Garenoxacin (12.5-50 mg/kg; s.c.; once) is highly effective against the wild-type strain and mutants harboring a single mutation in a mouse pneumonia model with S. pneumoniainfection[4].
Garenoxacin (10 and 30 mg/kg; p.o.; once) reduces the viable cell counts in the lungs and significantly prolongs survival on experimental secondary pneumococcal pneumonia caused by S. pneumoniae D-979 in BALB/c female mice[5].
| Animal Model: | Swiss mice with S. pneumonia infection[4]. |
| Dosage: | 12.5, 25 and 50 mg/kg |
| Administration: | Subcutaneous injection, once |
| Result: | Significantly improved the survival rate. |
IC 50
Quinolone; Gyrase: 1.25 μg/mL (IC50); TOPO IV: 1.5-2.5 μg/mL (IC50)
Garenoxacin Supplier
- Tel
- sales@boylechem.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- +86-400-851-9921
- sales@pharmacodia.com
Garenoxacin (223652-90-2)Related Product Information
- Garethelin Intermediate 1
- Garenoxacin Mesilate Hydrate iMpurity
- 2,3-Dihydro-(1R)-methyl-5-(tetrahydro-4H-1,3,6,2-dioxazaborocin-2-yl)-2-(triphenylmethyl)-1H-isoindole
- (1R)-5-bromo-2,3-dihydro-1-methyl-1H-Isoindole
- Garenoxacin Mesilate Hydrate impurity D
- Galesarin intermediate 3
- 1-PROPANONE, 1-[(1R)-5-BROMO-1,3-DIHYDRO-1-METHYL-2H-ISOINDOL-2-YL]-2,2-DIMETHYL-
- (R)-(1-methyl-2-tritylisoindolin-5-yl)boronic acid
- Galesarin intermediate 2
- Garenoxacin
- GARENOXACIN MESYLATE